Valuation: Profound Medical Corp.

Market Cap 304M 217M 189M 178M 162M 20.79B 305M 2.14B 825M 10.57B 814M 796M 34.02B P/E 2026 *
-6.93x
P/E 2027 * -10.2x
Enterprise Value 304M 217M 189M 178M 162M 20.79B 305M 2.14B 825M 10.57B 814M 796M 34.02B EV / Sales 2026 *
8.38x
EV / Sales 2027 * 5.11x
Free-Float
95.94%
Yield 2026 *
-
Yield 2027 * -
1 day+0.97%
1 week-0.84%
Current month-12.06%
1 month-14.77%
3 months-13.44%
6 months+17.71%
Current year-22.84%
1 week 7.86
Extreme 7.86
9.11
1 month 7.7
Extreme 7.7
10.21
Current year 6.52
Extreme 6.52
12.4
1 year 5.93
Extreme 5.93
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.51
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 2016-08-14
President 59 2026-08-31
Director of Finance/CFO - 2026-08-13
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 2018-06-13
Director/Board Member 79 2018-06-13
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Buy

Chairperson

10,000 0.0274%
9/11/26 Option

Director

739 0.0020%
9/11/26 Option

Chief Financial Officer

1,092 0.0030%
Change 5-day change 1-year change 3-year change Capi.($)
+0.97%-0.84%+39.43%-35.58% 217M
-1.04%+6.83%+35.84%+28.05% 241B
-0.32%+5.83%+9.58%-17.01% 149B
+2.55%+6.55%-10.35%+31.26% 139B
-0.48%+0.84%-55.70%-18.27% 62.81B
+0.01%+4.61%+18.61%+20.87% 50.87B
-1.69%-1.20%-19.89%-15.39% 48.21B
+0.08%+6.49%+23.87%+39.32% 44.11B
-1.88%+3.25%+40.14%+53.16% 41.42B
-2.27%+16.07%+133.21%+70.51% 36.18B
Average -0.41%+5.69%+21.47%+15.69% 81.26B
Weighted average by Cap. -0.26%+6.13%+15.57%+17.50%

Financials

2026 *2027 *
Net sales 36.22M 25.85M 22.54M 21.29M 19.33M 2.48B 36.37M 255M 98.39M 1.26B 97.11M 94.96M 4.06B 59.46M 42.44M 37.01M 34.95M 31.73M 4.07B 59.7M 419M 162M 2.07B 159M 156M 6.66B
Net income -44.08M -31.46M -27.44M -25.91M -23.53M -3.02B -44.26M -310M -120M -1.54B -118M -116M -4.94B -31.27M -22.32M -19.46M -18.38M -16.69M -2.14B -31.4M -220M -84.94M -1.09B -83.84M -81.98M -3.5B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
26-09-18 $8.310 +0.97% 11,060
26-09-17 $8.230 +0.61% 7,323
26-09-16 $8.180 +3.28% 5,886
26-09-15 $7.920 -1.37% 12,422
26-09-14 $8.030 -4.18% 16,492
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.310
Average target price
-

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!